Target(s)
- Oticon Medical A/S
Summary
Cochlear Limited (Cochlear) proposes to acquire the shares and certain assets of Oticon Medical A/S (Oticon Medical) from Demant A/S.
In Australia, Cochlear and Oticon Medical both supply hearing solutions, specifically cochlear implants and bone conduction solutions.
Market inquiries
The ACCC has published a Statement of Issues outlining preliminary competition concerns in relation to the proposed acquisition.
The ACCC invites submissions on its Statement of Issues by close of business on 22 December 2022.
Submissions should be forwarded electronically (preferably in PDF format) to mergers@accc.gov.au with the title “Submission re: Cochlear/Oticon Medical – attention Annabel Garrard / Marisa Kuhlewein”.
Following 22 December 2022, queries regarding the ACCC's review may be addressed to Annabel Garrard / Marisa Kuhlewein at mergers@accc.gov.au
For more details, please refer to the attached Statement of Issues.
Market inquiries
Statement of issues
Timeline
Date | Event |
---|---|
04/08/2022 | ACCC commenced informal review under the Informal Merger Review Process Guidelines. |
23/08/2022 | Closing date for submissions. |
12/10/2022 | ACCC is awaiting information from the parties. Former provisional date for announcement of findings (27 October 2022) is delayed. |
16/11/2022 | ACCC timeline recommenced. |
01/12/2022 | ACCC published a Statement of Issues outlining preliminary competition concerns. |
22/12/2022 | Closing date for submissions relating to Statement of Issues. |
30/01/2023 | Timeline suspended pending receipt of information from the parties. Former provisional date for announcement of ACCC's findings (16 March 2023) is delayed. The ACCC will announce a proposed decision date in due course. |
Project staff
- Marisa Kuhlewein
- Annabel Garrard